This is a summary of the European public assessment report (EPAR) for Kentera. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Kentera.
Therapeutic Indication
### Therapeutic indication Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder.
Therapeutic Area (MeSH)
ATC Code
G04BD04
ATC Item
oxybutynin
Pharmacotherapeutic Group
Urologicals
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| oxybutynin | N/A | 奥昔布宁 |
EMA Name
Kentera (previously Oxybutynin Nicobrand)
Medicine Name
Kentera (previously Oxybutynin Nicobrand)
Aliases
N/ANo risk management plan link.
